Filana lifts FDA临床hold on simufilam for TSC-related epilepsy
Filana announced the FDA lifted the clinical hold on simufilam in Q3, expecting patient screening to begin by Q1 2027; the company reported $47.0 million in cash with R&D expenses decreasing 2%.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed